MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Dollar
Positive Cash Flow Breakdown
Accounts payable and accrued exp...
Proceeds from issuance of common...
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Vat receivable
Prepaid expenses
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-8,632,386
-10,396,831
-13,460,833
-6,879,530
Depreciation and amortization expense
124,938
124,938
124,938
124,938
Change in value of warrant liabilities
-
-
-
0
Changes in fair value of warrant liability
-
0
0
-
Commitment shares issued for equity line of credit
-
0
0
0
Amortization of debt issuance costs and warrants
5,109
68,972
0
-
Shares issued for services
42,000
289,200
0
239,253
Stock-based compensation expense
1,331,111
1,435,362
1,604,560
814,932
Prepaid expenses
337,707
-63,082
-340,131
-348,750
Employee advances
-
-
-
-41,852
Shares issued for services
-
-
0
-
Accounts payable
-
-
6,562,097
671,563
Vat receivable
3,097,825
-
-
-
Amortization of debt discounts issuance and warrants
-
-
-
0
Shares issued for interest expense
-
-
0
-
Accounts payable and accrued expenses
5,014,043
3,882,449
1,019,552
15,140
Accrued interest on convertible notes
-472
-6,372
0
0
Accrued payroll and payroll taxes
17,373
-37,082
37,457
614
Net cash used in operating activities
-5,532,872
-4,563,538
-3,730,246
-4,706,192
Shareholder loan repayment
-
0
-
-
Patent license acquisition
-
0
0
0
Net cash used in investing activities
-
0
0
0
Proceeds from warrant exercises (net of issuance costs)
0
3,376,260
530,162
-
Common stock issuance (net of fees)
-
-
1,593,870
3,780,805
Sale of preferred stock
-
-
-582
0
Short-term borrowings
-
-
0
0
Short-term loan repayments
-
-
0
0
Initial public offering (net of fees)
-
-
0
0
Proceeds from convertible notes (net of issuance costs)
0
1,835,000
0
0
Proceeds from issuance of common stock and warrants in connection with registered direct offering
4,820,355
0
-
-
Net cash provided by financing activities
4,820,355
5,211,260
2,123,450
3,780,805
Net change in cash and cash equivalents
-712,517
647,722
-1,606,796
-925,387
Cash and cash equivalents beginning of period
917,552
269,830
1,876,626
5,533,527
Cash and cash equivalents end of period
205,035
917,552
269,830
1,876,626
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock and...
$4,820,355
Net cash provided by
financing activities
$4,820,355
(36.28%↑ Y/Y)
Net change in cash
and cash...
-$712,517
(73.91%↑ Y/Y)
Canceled cashflow
$4,820,355
Accounts payable and
accrued expenses
$5,014,043
(3663.64%↑ Y/Y)
Stock-based compensation
expense
$1,331,111
(-27.91%↓ Y/Y)
Depreciation and
amortization expense
$124,938
(10.36%↑ Y/Y)
Shares issued for
services
$42,000
(-88.22%↓ Y/Y)
Accrued payroll and
payroll taxes
$17,373
(117.86%↑ Y/Y)
Amortization of debt issuance
costs and warrants
$5,109
Accrued interest on
convertible notes
-$472
Net cash used in
operating activities
-$5,532,872
(4.64%↑ Y/Y)
Canceled cashflow
$6,535,046
Net loss
-$8,632,386
(-2.60%↓ Y/Y)
Vat receivable
$3,097,825
Prepaid expenses
$337,707
(196.83%↑ Y/Y)
Buy us a coffee
OS Therapies Inc (OSTX)
OS Therapies Inc (OSTX)